Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer.

doi:10.1016/j.ejca.2020.03.025

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer.

European journal of cancer (Oxford, England : 1990) - 1 Jun 2020

Facchinetti Francesco, Lacroix Ludovic, Mezquita Laura, Scoazec Jean-Yves, Loriot Yohann, Tselikas Lambros, Gazzah Anas, Rouleau Etienne, Adam Julien, Michiels Stefan, Massard Christophe, André Fabrice, Olaussen Ken A, Vassal Gilles, Howarth Karen, Besse Benjamin, Soria Jean-Charles, Friboulet Luc, Planchard David

Abstract excerpt

INTRODUCTION: BRAF is a confirmed therapeutic target in non-small cell lung cancer (NSCLC), as the BRAF inhibitor dabrafenib, in combination with the MEK inhibitor trametinib, is approved for the treatment of NSCLC harbouring BRAF V600E mutation. Scant evidence is available concerning the mechanisms of resistance to BRAF/MEK inhibitors in BRAFV600E NSCLC. PATIENTS AND METHODS: Patients with BRAFV600E NSCLC with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Follow-Up Studies

Share to Lung Neoplasms

Share to MAP Kinase Kinase Kinases

Share to Prognosis

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed

Identifiers

PMID: 32388065
DOI: 10.1016/j.ejca.2020.03.025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer.PMID 32388065Read ↗

MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient.Semantic proximity Read ↗

Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.Semantic proximity Read ↗

How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.Semantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2Semantic proximity Read ↗

Ongoing progress in BRAF-mutated non-small cell lung cancer.Semantic proximity Read ↗

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitorsSemantic proximity Read ↗

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.Semantic proximity Read ↗

A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.Semantic proximity Read ↗

Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.Semantic proximity Read ↗

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.